DiaPat - the key to your health
DiaPat GmbH was founded in Hanover in 2003. The company offers diagnostic tests for the early detection of diseases and is a leader in this field due to its innovative technology. The method is based on the analysis of proteins that play an outstanding role as information carriers in the human body. In addition to diagnostics, the DiaPat® procedure also enables therapy monitoring in the sense of personalized medicine.
The main corporate goal is to enable the early detection of diseases, significantly improve the prospects of healing and thus contribute to an improved quality of life for people and the affected patients.
As a leading biotech company in the field of clinical protein analysis in urine (UPA), DiaPat and the parent company mosaiques diagnostics are recognized cooperation partners of renowned university clinics all over the world. The UPA test has been the subject of numerous multicentre studies, including many EU consortia.
The idea - and how it all started ...
In 2000, the biochemist Prof. Dipl. Ing. Dr. med. habil. Harald Mischak and the nephrologist Prof. Dr. med. Hermann Haller from the Hannover Medical School (MHH) the biotech company Mosaiques-diagnostics GmbH. Prof. Mischak brought in his decades of experience in the field of protein and peptide analysis, which he had gathered in the USA at the National Institute of Health (NIH).
The basis of the company was the early and reliable detection of diseases, if possible before organ damage, through a comprehensive, fast and exact analysis of messenger substances in body fluids, the proteins. It was already known back then: There are measurable differences in the "proteome", the entirety of all human proteins, between healthy and sick people - specifically for different diseases. This paved the way for researching disease-related protein patterns ("diagnostic patterns", DiaPats).
How does a good idea find an investor?
In 2001 Prof. Mischak was looking for a financier to implement his idea. The timing was obviously poor. Many biotechnology companies and venture capital had just entered an existential crisis. The capital markets no longer provided sufficient money for the complicated projects to be carried out over long periods. At almost the same time, the Hanover business lawyer Joachim Conrads was looking for an investment opportunity in the biotech industry. He had already examined several dozen projects until he happened to meet Prof. Mischak at an event organized by the Lower Saxony Ministry of Economics in May 2002.
He presented his protein analysis technology there. During the break in the event he discussed with Mr. Conrads so enthusiastically that his red wine landed on the jacket of the potential investor. Mischak's idea was as persistent as the red wine in the jacket in Conrads' head. Two months later, he invested in Mosaiques diagnostics GmbH for the first time.
A family of companies grows out of the idea.
As is quite common in the early stages of start-ups, the amount of work multiplied while specializing. A new parent company, Mosaiques diagnostics and therapeutics AG, was created as the holding company and sole shareholder of the original Mosaiques diagnostics GmbH. The latter, in turn, specialized in biotechnological research and development work. In addition, DiaPat GmbH was founded as a submission laboratory for routine diagnostics.
First studies, growing need for the DiaPat® test.
The first attempts to build up studies started. The abundance of possible applications for the DiaPat® test was not foreseeable at this point. The only thing that was clear was that it is particularly suitable for the early detection of diseases. Long before the first symptoms appear or even organs are damaged. As a result, the DiaPat® process would quickly develop into an important component of modern medicine, virtually without competition. Supposed competitors appeared, technological competition appeared, and they disappeared. However, left a bad reputation for molecular diagnostics.
The first good product, tailwind and headwind.
Then finally, in late 2005: the first good product. Product that was good for his time, as it quickly became clear : The urologists were up in arms against the DiaPat® PC test . But there were other voices too. More and more doctors from all over the world and from various faculties signaled enthusiasm for the Mischak method, became public advocates and continue to use their expertise to develop and research new disease-specific protein patterns.
Is the DiaPat® test paid for today by the health insurance companies?
The DiaPat® test still seems to be too new to be considered the standard in medical science and technology. It is still missing in the service catalog of the statutory health insurance companies and in medical guidelines. Still, because:
As early as 2009, the Federal Institute for Drugs and Medical Devices and the associated lower supervisory authorities, the trade supervisory authorities of the federal states, decided that the DiaPat® PC test, as described in the studies, may be offered after a positive PSA test.
In July 2011, the National Association of Statutory Health Insurance Physicians (KBV) applied for the evaluation of " proteome analysis in urine for the detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension ". The Federal Joint Committee (G-BA) then decided in December 2012 to commission the Institute for Quality and Efficiency in Health Care (IQWiG) with the assessment. The G-BA also published the advisory topic in the Federal Gazette.
However: As an IGeL service, DiaPat® tests have been on the market for years and can be billed by the doctor (via the GOÄ with an analog number). In addition, some advanced private health insurers and subsidy agencies have already covered the costs in individual cases.